Cover ImageSALE
市場調查報告書

亞太地區的癲癇治療藥市場:2017年∼2021年

Epilepsy Therapeutic Market in APAC 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 322239
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的癲癇治療藥市場:2017年∼2021年 Epilepsy Therapeutic Market in APAC 2017-2021
出版日期: 2017年06月07日 內容資訊: 英文 81 Pages
簡介

亞太地區地區的癲癇治療藥市場,預計從2017年到2021年之間,以4.25%的CAGR(年複合成長率)擴大。

本報告提供亞太地區癲癇治療藥現況與今後的預測,各地區的市場規模和未來預測,市場成長因素與課題,並提供主要企業簡介等資訊。

第1章 摘要整理

第2章 調查範圍

第3章 市場調查手法

第4章 簡介

第5章 疾病概要

  • 徵兆與症狀
  • 全身發作
  • 焦點性發作
  • 非痙攣發作

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 開發平台分析

第8章 各產品類型的市場區隔

  • 第1代癲癇治療藥
  • 第2代的癲癇治療藥
  • 第3代癲癇治療藥

第9章 各地區的市場區隔

  • 日本的癲癇治療藥市場
  • 澳洲的癲癇治療藥市場
  • 中國的癲癇治療藥市場
  • 印度的癲癇治療藥市場

第10章 決策結構

第11章 市場成長因素與課題

第12章 市場趨勢

第13章 業者情勢

  • 競爭模式

第14章 主要供應商分析

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
  • 其他卓越供應商

第15章 附錄

  • 簡稱清單

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR13236

About Epilepsy Therapeutic

Epilepsy is a neurological condition that affects the nervous system. It is characterized by the occurrence of two or more unprovoked seizures. A seizure is defined as the disruption of electrical communication between neurons. The central nervous system (CNS) disorders include several disorders and conditions such as epilepsy, Parkinson's disease, bipolar disorder, and depression.

Technavio's analysts forecast the epilepsy therapeutic market in APAC to grow at a CAGR of 4.25% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the epilepsy therapeutic market in APAC for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Epilepsy Therapeutic Market in APAC 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

Other Prominent Vendors

  • Dainippon Sumitomo Pharma
  • Janssen Pharmaceutical (a division of Johnson & Johnson)

Market driver

  • High unmet medical need
  • For a full, detailed list, view our report

Market challenge

  • Technological advancements in non-invasive neuromodulation and seizure management devices - A threat to drug therapies
  • For a full, detailed list, view our report

Market trend

  • Reformulation of marketed drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Disease overview

  • Signs and symptoms
  • Generalized seizure
  • Focal seizure
  • Non-convulsive seizure

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Pipeline analysis

PART 08: Market segmentation based on product type

  • First-generation epilepsy therapeutics
  • Second-generation epilepsy therapeutics
  • Third-generation epilepsy therapeutics

PART 09: Geographical segmentation

  • Epilepsy therapeutics market scenario in Japan
  • Market scenario in Australia
  • Market scenario in China
  • Market scenario in India

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Reformulation of marketed drugs
  • Emergence of new-generation AEDs
  • AEDs with novel mechanism of action

PART 13: Vendor landscape

  • Competitive landscape

PART 14: Key vendor analysis

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global CNS therapeutics market segmentation based on disease type
  • Exhibit 02: Epilepsy therapeutics market scenario based on countries
  • Exhibit 03: Types of epilepsy disorder
  • Exhibit 04: Signs and symptoms of epilepsy
  • Exhibit 05: Types of generalized seizure
  • Exhibit 06: Types of focal seizure
  • Exhibit 07: Epilepsy therapeutics market in APAC snapshot
  • Exhibit 08: Epilepsy therapeutics market in APAC 2016-2021 (in $ million)
  • Exhibit 09: Opportunity analysis in epilepsy therapeutics market in APAC
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Pipeline landscape
  • Exhibit 12: Key clinical trials: Therapeutics
  • Exhibit 13: Key clinical trials: Enhanced drug delivery
  • Exhibit 14: Key clinical trials: Dietary supplement
  • Exhibit 15: Segmentation of epilepsy therapeutics market in APAC on product type
  • Exhibit 16: Market share of epilepsy therapeutics market in APAC based on product type 2016
  • Exhibit 17: Approval scenario: First-generation epilepsy therapeutics
  • Exhibit 18: First-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 19: Second-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 20: Third-generation epilepsy therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 21: Segmentation of epilepsy therapeutics market in APAC by geography 2016 and 2021 (%)
  • Exhibit 22: Epilepsy therapeutics market revenue in APAC by geography 2016-2021 ($ millions)
  • Exhibit 23: Epilepsy therapeutics market share in APAC by geography 2016-2021 (%)
  • Exhibit 24: Market scenario in Japan
  • Exhibit 25: Epilepsy therapeutics market in Japan 2016-2021 ($ millions)
  • Exhibit 26: Market scenario in Australia
  • Exhibit 27: Epilepsy therapeutics market in Australia 2016-2021 ($ millions)
  • Exhibit 28: Market scenario in China
  • Exhibit 29: Epilepsy therapeutics market in China 2016-2021 ($ millions)
  • Exhibit 30: Market scenario in India
  • Exhibit 31: Epilepsy therapeutics market in India 2016-2021 ($ millions)
  • Exhibit 32: Epilepsy scenario in developed countries versus developing countries
  • Exhibit 33: Impact of loss of exclusivity for LYRICA in Canadian and European market ($ millions)
  • Exhibit 34: Competitive structure analysis of epilepsy therapeutics market in APAC 2016
  • Exhibit 35: Eisai: Key highlights
  • Exhibit 36: Eisai: Strength assessment
  • Exhibit 37: Eisai: Strategy assessment
  • Exhibit 38: Eisai: Opportunity assessment
  • Exhibit 39: GlaxoSmithKline: Strength assessment
  • Exhibit 40: GlaxoSmithKline: Strategy assessment
  • Exhibit 41: GlaxoSmithKline: Opportunity assessment
  • Exhibit 42: Pfizer: Key highlights
  • Exhibit 43: Pfizer: Strength assessment
  • Exhibit 44: Pfizer: Strategy assessment
  • Exhibit 45: Pfizer: Opportunity assessment
  • Exhibit 46: UCB: Key highlights
  • Exhibit 47: UCB: Strength assessment
  • Exhibit 48: UCB: Strategy assessment
  • Exhibit 49: UCB: Opportunity assessment
Back to Top